Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
Status:
Terminated
Trial end date:
2019-07-11
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225
mg of Rapastinel compared to placebo in the prevention of relapse in participants with major
depressive disorder (MDD).